The Efficacy and Safety of Iodine-۱۲۵ Implantation Combined with Gemcitabine in the Treatment of Advanced Pan- creatic Cancer: A Systematic Review and Meta-analysis
- سال انتشار: 1400
- محل انتشار: مجله تحقیقات سرطان، دوره: 5، شماره: 3
- کد COI اختصاصی: JR_MCIJO-5-3_002
- زبان مقاله: انگلیسی
- تعداد مشاهده: 439
نویسندگان
Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China & Department of Postgraduate, Qinghai University, Xining, China
Department of Orthopedics, Sichuan People's Hospital, Chengdu, China & Department of Postgraduate, Chengdu Medical College, Chengdu, China
Department of Radiology, Chengdu Medical College, Chengdu, China
Department of Ultrasound Medicine, People’s Hospital of Tibet Autonomous Region, Lhasa, China ; Department of Postgraduate, Tibet University, Lhasa, China
Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China
Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China
Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China
چکیده
Introduction: A systematic review and meta-analysis was conducted to assess the efficacy and safety of iodine-۱۲۵ implantation combined with gemcitabine in the treatment of advanced pancreatic cancer. Methods: PubMed, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, Embase, and Wanfang database through Oct ۲۰۲۰ were searched for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy and safety of iodine-۱۲۵ implantation combined with gemcitabine in the treatment of advanced pancreatic cancer. The main outcome measures included the overall remission [complete response (CR)+partial response (PR)] rate, overall survival (OS), hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events. Results: Totally, ۱۹ studies involving ۱۴۹۶ patients were included in the current systematic review and meta-analysis. The pooled results showed that efficacy and safety of patients treated with Iodine-۱۲۵ combined with gemcitabine were superior to those undergoing gemcitabine alone: overall remission (CR+PR) rate [odds ratio (OR)=۳.۱۰, ۹۵% confidence interval (CI): ۲.۴۰, ۴.۰۰; P< ۰.۰۰۰۰۱], OS [hazard ratio (HR)=۰.۵۶, ۹۵% CI: ۰.۴۷, ۰.۶۸; P< ۰.۰۰۰۰۱], hypofunction of liver (OR=۱.۰۸, ۹۵% CI: ۰.۶۷, ۱.۷۴; P=۰.۷۵), CBR rate (OR=۳.۸۵, ۹۵% CI: ۲.۸۳, ۵.۲۲; P< ۰.۰۰۰۰۱), survival rate of six months (OR=۳.۴۴ ۹۵% CI: ۱.۸۳, ۶.۴۶) and survival rate of ۱۲ months (OR=۲.۶۷, ۹۵% CI: ۱.۶۸, ۴.۲۶). And there was no statistical association in adverse events between the groups. Conclusions: The combination of iodine-۱۲۵ seed implantation and gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.کلیدواژه ها
Iodine-۱۲۵, Pancreatic Neoplasms, Meta-Analysis, Gemcitabineاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.